Provided by Tiger Trade Technology Pte. Ltd.

Nymox Pharmaceutical

0.2000
0.0000
Volume:- -
Turnover:188.90K
Market Cap:18.25M
PE:-5.61
High:0.2000
Open:0.2000
Low:0.2000
Close:0.2000
52wk High:0.7427
52wk Low:0.1688
Shares:91.27M
Float Shares:50.87M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0356
EPS(LYR):-0.0736
ROE:-683.11%
ROA:-204.29%
PB:-10.15
PE(LYR):-2.72

Loading ...

Company Profile

Company Name:
Nymox Pharmaceutical
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.